Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
Abstract Sarcomas are a group of diverse and complex cancers of mesenchymal origin that remains poorly understood. Recent developments in cancer immunotherapy have demonstrated a potential for better outcomes with immune checkpoint inhibition in some sarcomas compared to conventional chemotherapy. I...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-08-01
|
| Series: | Biomarker Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40364-023-00513-5 |
| _version_ | 1797557503122210816 |
|---|---|
| author | Chin Sern Yiong Tzu Ping Lin Vivian Yujing Lim Tan Boon Toh Valerie Shiwen Yang |
| author_facet | Chin Sern Yiong Tzu Ping Lin Vivian Yujing Lim Tan Boon Toh Valerie Shiwen Yang |
| author_sort | Chin Sern Yiong |
| collection | DOAJ |
| description | Abstract Sarcomas are a group of diverse and complex cancers of mesenchymal origin that remains poorly understood. Recent developments in cancer immunotherapy have demonstrated a potential for better outcomes with immune checkpoint inhibition in some sarcomas compared to conventional chemotherapy. Immune checkpoint inhibitors (ICIs) are key agents in cancer immunotherapy, demonstrating improved outcomes in many tumor types. However, most patients with sarcoma do not benefit from treatment, highlighting the need for identification and development of predictive biomarkers for response to ICIs. In this review, we first discuss United States (US) Food and Drug Administration (FDA)-approved and European Medicines Agency (EMA)-approved biomarkers, as well as the limitations of their use in sarcomas. We then review eight potential predictive biomarkers and rationalize their utility in sarcomas. These include gene expression signatures (GES), circulating neutrophil-to-lymphocyte ratio (NLR), indoleamine 2,3-dioxygenase (IDO), lymphocyte activation gene 3 (LAG-3), T cell immunoglobin and mucin domain-containing protein 3 (TIM-3), TP53 mutation status, B cells, and tertiary lymphoid structures (TLS). Finally, we discuss the potential for TLS as both a predictive and prognostic biomarker for ICI response in sarcomas to be implemented in the clinic. |
| first_indexed | 2024-03-10T17:17:49Z |
| format | Article |
| id | doaj.art-0527484d94724ff8b1871d82e5e27d18 |
| institution | Directory Open Access Journal |
| issn | 2050-7771 |
| language | English |
| last_indexed | 2024-03-10T17:17:49Z |
| publishDate | 2023-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Biomarker Research |
| spelling | doaj.art-0527484d94724ff8b1871d82e5e27d182023-11-20T10:25:01ZengBMCBiomarker Research2050-77712023-08-0111113010.1186/s40364-023-00513-5Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?Chin Sern Yiong0Tzu Ping Lin1Vivian Yujing Lim2Tan Boon Toh3Valerie Shiwen Yang4Translational Precision Oncology Laboratory, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR)Translational Precision Oncology Laboratory, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR)Translational Precision Oncology Laboratory, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR)The N.1 Institute for Health, National University of SingaporeTranslational Precision Oncology Laboratory, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR)Abstract Sarcomas are a group of diverse and complex cancers of mesenchymal origin that remains poorly understood. Recent developments in cancer immunotherapy have demonstrated a potential for better outcomes with immune checkpoint inhibition in some sarcomas compared to conventional chemotherapy. Immune checkpoint inhibitors (ICIs) are key agents in cancer immunotherapy, demonstrating improved outcomes in many tumor types. However, most patients with sarcoma do not benefit from treatment, highlighting the need for identification and development of predictive biomarkers for response to ICIs. In this review, we first discuss United States (US) Food and Drug Administration (FDA)-approved and European Medicines Agency (EMA)-approved biomarkers, as well as the limitations of their use in sarcomas. We then review eight potential predictive biomarkers and rationalize their utility in sarcomas. These include gene expression signatures (GES), circulating neutrophil-to-lymphocyte ratio (NLR), indoleamine 2,3-dioxygenase (IDO), lymphocyte activation gene 3 (LAG-3), T cell immunoglobin and mucin domain-containing protein 3 (TIM-3), TP53 mutation status, B cells, and tertiary lymphoid structures (TLS). Finally, we discuss the potential for TLS as both a predictive and prognostic biomarker for ICI response in sarcomas to be implemented in the clinic.https://doi.org/10.1186/s40364-023-00513-5Immune checkpoint inhibitorsPredictive biomarkersSarcomasTertiary lymphoid structures |
| spellingShingle | Chin Sern Yiong Tzu Ping Lin Vivian Yujing Lim Tan Boon Toh Valerie Shiwen Yang Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation? Biomarker Research Immune checkpoint inhibitors Predictive biomarkers Sarcomas Tertiary lymphoid structures |
| title | Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation? |
| title_full | Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation? |
| title_fullStr | Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation? |
| title_full_unstemmed | Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation? |
| title_short | Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation? |
| title_sort | biomarkers for immune checkpoint inhibition in sarcomas are we close to clinical implementation |
| topic | Immune checkpoint inhibitors Predictive biomarkers Sarcomas Tertiary lymphoid structures |
| url | https://doi.org/10.1186/s40364-023-00513-5 |
| work_keys_str_mv | AT chinsernyiong biomarkersforimmunecheckpointinhibitioninsarcomasareweclosetoclinicalimplementation AT tzupinglin biomarkersforimmunecheckpointinhibitioninsarcomasareweclosetoclinicalimplementation AT vivianyujinglim biomarkersforimmunecheckpointinhibitioninsarcomasareweclosetoclinicalimplementation AT tanboontoh biomarkersforimmunecheckpointinhibitioninsarcomasareweclosetoclinicalimplementation AT valerieshiwenyang biomarkersforimmunecheckpointinhibitioninsarcomasareweclosetoclinicalimplementation |